Pathology Medicare Benefits Schedule (MBS) item changes for 1 September 2022

From 1 September 2022, items 73295 and 73301 will be amended to replace the specific drug name of ‘olaparib’ with the name of the class of drugs ‘poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor’.

The changes to these items permits them to be used to determine Pharmaceutical Benefits Scheme (PBS) eligibility for not only olaparib, but also niraparib and other PARP inhibitors that may be approved in the future by Pharmaceutical Benefits Advisory Committee (PBAC) for listing on the PBS in regard to the treatment of the conditions listed in items 73295 and 73301.

PDF version Amendment to MBS items 73295 and 73301 for BRCA1 and BRCA2 status testing (PDF 283 KB)
Word version Amendment to MBS items 73295 and 73301 for BRCA1 and BRCA2 status testing (Word 119 KB)